Grace Therapeutics, Inc. (GRCE) Dividend History

Grace Therapeutics, Inc. (GRCE) is a biopharmaceutical company focused on developing innovative therapies for the treatment of neurological and neurological-related disorders. The company engages in the identification, development, and commercialization of novel medications designed to address unmet medical needs in various medical conditions.

Dividend History

Grace Therapeutics, Inc. currently does not pay dividends

Company News

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Grace Therapeutics announced that its Phase 3 STRIVE-ON trial for GTx-104, a novel injectable formulation of nimodipine, met its primary endpoint and showed evidence of clinical benefit over oral nimodipine in aSAH patients. The company plans to submit a New Drug Application (NDA) for GTx-104 in the first half of 2025.

GlobeNewswire Inc.

Page data last updated 08/19/2025 16:47:30 UTC